Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MGD-014 by MacroGenics for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
MGD-014 is under clinical development by MacroGenics and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According...
Vobramitamab duocarmazine by MacroGenics for Small-Cell Lung Cancer: Likelihood of Approval
Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
MGC-026 by MacroGenics for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...
MGC-026 by MacroGenics for Metastatic Breast Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase...
MGC-026 by MacroGenics for Bladder Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I...
MGC-026 by MacroGenics for Gastric Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
MGC-026 by MacroGenics for Cervical Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...
Vobramitamab duocarmazine by MacroGenics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
Vobramitamab duocarmazine by MacroGenics for Anal Cancer: Likelihood of Approval
Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Anal Cancer. According to GlobalData, Phase...
MGD-024 by MacroGenics for Hairy Cell Leukemia: Likelihood of Approval
MGD-024 is under clinical development by MacroGenics and currently in Phase I for Hairy Cell Leukemia. According to GlobalData, Phase...
Vobramitamab duocarmazine by MacroGenics for Ovarian Cancer: Likelihood of Approval
Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
MGD-024 by MacroGenics for Systemic Mastocytosis: Likelihood of Approval
MGD-024 is under clinical development by MacroGenics and currently in Phase I for Systemic Mastocytosis. According to GlobalData, Phase I...
Vobramitamab duocarmazine by MacroGenics for Renal Cell Carcinoma: Likelihood of Approval
Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Renal Cell Carcinoma. According to GlobalData,...
Vobramitamab duocarmazine by MacroGenics for Hepatocellular Carcinoma: Likelihood of Approval
Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...
Vobramitamab duocarmazine by MacroGenics for Pancreatic Cancer: Likelihood of Approval
Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
Vobramitamab duocarmazine by MacroGenics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
MGD-024 by MacroGenics for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
MGD-024 is under clinical development by MacroGenics and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic...
Vobramitamab duocarmazine by MacroGenics for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval
Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC). According to...
Vobramitamab duocarmazine by MacroGenics for Melanoma: Likelihood of Approval
Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Melanoma. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of MacroGenics's Vobramitamab Duocarmazine?
Vobramitamab Duocarmazine is a monoclonal antibody conjugated commercialized by MacroGenics, with a leading Phase II program in Anal Cancer. According...